Researchers have developed a new blood test that measures mitochondrial DNA damage as a potential marker for Parkinson’s disease (PD). The study shows the test could aid in diagnosing PD and assessing responses to LRRK2 kinase inhibitors, which may help in reducing mitochondrial damage in PD patients.
PRECISIS GmbH celebrates Win at the Innovation Award of the Federal State Baden-Württemberg 2023 – Biotech Investments
Issuer: PRECISIS GmbH / Key word(s): Miscellaneous 22.11.2023 / 14:57 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg, November 22nd
November 23, 2023